Analytical Diagnostic Solutions Inc.

Analytical Diagnostic Solutions Inc., based in Mt Laurel, New Jersey, is a for-profit corporation developing point-of-care diagnostic devices for rare genetic and metabolic disorders as a federal grant recipient, exclusively under National Institutes of Health (NIH) and National Science Foundation funding with no federal contracts in its current portfolio. The company operates 100% as a prime recipient on research grants focused on biomarker detection and home monitoring platforms for hyperoxaluria, homocysteinemia, creatine phosphokinase deficiency, phenylketonuria, and adenosine deaminase 2 deficiency.

Analytical Diagnostic Solutions' customer concentration tracks entirely within the Department of Health and Human Services research ecosystem. Ten of thirteen total awards (77%) flow through four NIH institutes: the National Institute of Allergy and Infectious Diseases (3 awards), the National Institute of Child Health and Human Development (3 awards), the National Institute of General Medical Sciences (2 awards), and the National Institute of Diabetes and Digestive and Kidney Diseases (1 award). Combined obligated dollars across all awards total $15.6 million. Recent representative work includes a $311,172 award from NIDDK dated August 15, 2026, to develop a point-of-care device for monitoring urinary oxalate levels in patients with oxalurias and kidney stone disease under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), running through July 31, 2027; a homocysteine point-of-care test development grant from the National Center for Advancing Translational Sciences under the SBIR/STTR omnibus solicitation, awarded July 1, 2025, with completion August 31, 2026; and two overlapping awards from the National Institute of Child Health and Human Development for creatine phosphokinase point-of-care device development, awarded September 20, 2023, with completions spanning August 31, 2024, through August 31, 2027.

Activity spans thirteen awards distributed across 2017 through 2026, with a cluster of four awards in 2023 followed by sparse volume in 2025 and 2026. Two awards face ultimate completion within the next twenty-four months. The company's core capability centers on colorimetric detection platforms using reflectance-meter technology with finger-stick or heel-stick blood sampling, deployed across multiple rare-disease biomarker applications. No subcontracting activity or commercial contract vehicles appear in the portfolio; all work remains within NIH research grant programs targeting unmet diagnostic needs in pediatric and adult rare metabolic diseases.

Research & Development Biotechnology